Novocure Stock Performance
| NVCR Stock | USD 25.51 0.01 0.04% |
On a scale of 0 to 100, Novocure holds a performance score of 10. The company secures a Beta (Market Risk) of 0.0689, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Novocure's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novocure is expected to be smaller as well. Please check Novocure's downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Novocure's current price movements will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Novocure are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental indicators, Novocure reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.20) | Five Day Return (5.13) | Year To Date Return (14.90) | Ten Year Return 16 | All Time Return 16 |
1 | Disposition of tradable shares by Mukund Paravasthu of Novocure at 16.6858 subject to Rule 16b-3 | 11/01/2024 |
2 | Novocures oncology president sells 9,530 in shares | 11/04/2024 |
3 | Novocure therapy succeeds in pancreatic cancer trial | 12/02/2024 |
4 | Novocure annonce des rsultats positifs de lessai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs pour le cancer du pancras | 12/05/2024 |
5 | Why NovoCure Stock Was Winning Big This Week | 12/06/2024 |
6 | Acquisition by Leupin Nicolas of 78174 shares of Novocure at 16.3 subject to Rule 16b-3 | 12/27/2024 |
7 | Acquisition by Asaf Danziger of 412 shares of Novocure at 14.748 subject to Rule 16b-3 | 12/31/2024 |
8 | Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference | 01/03/2025 |
9 | Investing in NovoCure a year ago would have delivered you a 97 percent gain | 01/08/2025 |
10 | Disposition of 2160 shares by Mukund Paravasthu of Novocure at 26.8084 subject to Rule 16b-3 | 01/10/2025 |
11 | Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update | 01/13/2025 |
12 | NovoCure Ltd Shares Down 3.67 percent on Jan 14 - GuruFocus.com | 01/15/2025 |
13 | Acquisition by Hilleman Jeryl L of 4053 shares of Novocure subject to Rule 16b-3 | 01/17/2025 |
14 | Investing in NovoCure a year ago would have delivered you a 85 percent gain | 01/21/2025 |
| Begin Period Cash Flow | 115.8 M |
Novocure |
Novocure Relative Risk vs. Return Landscape
If you would invest 1,618 in Novocure on November 1, 2024 and sell it today you would earn a total of 933.00 from holding Novocure or generate 57.66% return on investment over 90 days. Novocure is currently generating 0.9813% in daily expected returns and assumes 7.3619% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Novocure, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novocure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novocure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novocure, and traders can use it to determine the average amount a Novocure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1333
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NVCR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.36 actual daily | 65 65% of assets are less volatile |
Expected Return
| 0.98 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Novocure is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novocure by adding it to a well-diversified portfolio.
Novocure Fundamentals Growth
Novocure Stock prices reflect investors' perceptions of the future prospects and financial health of Novocure, and Novocure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novocure Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0793 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 2.48 B | ||||
| Shares Outstanding | 108.2 M | ||||
| Price To Earning | 721.15 X | ||||
| Price To Book | 7.67 X | ||||
| Price To Sales | 4.78 X | ||||
| Revenue | 509.34 M | ||||
| Gross Profit | 442.26 M | ||||
| EBITDA | (175.87 M) | ||||
| Net Income | (207.04 M) | ||||
| Cash And Equivalents | 948.52 M | ||||
| Cash Per Share | 9.06 X | ||||
| Total Debt | 596.24 M | ||||
| Debt To Equity | 1.31 % | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | 3.34 X | ||||
| Cash Flow From Operations | (73.34 M) | ||||
| Earnings Per Share | (1.39) X | ||||
| Market Capitalization | 2.76 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (985.5 M) | ||||
| Working Capital | 855.29 M | ||||
| Current Asset | 293.9 M | ||||
| Current Liabilities | 28.63 M | ||||
About Novocure Performance
Assessing Novocure's fundamental ratios provides investors with valuable insights into Novocure's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Novocure is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 124.84 | 138.46 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.51) | (0.54) |
Things to note about Novocure performance evaluation
Checking the ongoing alerts about Novocure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novocure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novocure is way too risky over 90 days horizon | |
| Novocure appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 509.34 M. Net Loss for the year was (207.04 M) with profit before overhead, payroll, taxes, and interest of 442.26 M. | |
| Novocure currently holds about 948.52 M in cash with (73.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06. | |
| Novocure has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Investing in NovoCure a year ago would have delivered you a 85 percent gain |
- Analyzing Novocure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novocure's stock is overvalued or undervalued compared to its peers.
- Examining Novocure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novocure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novocure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novocure's stock. These opinions can provide insight into Novocure's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.